#USA #Boston #Clinical Trials #PhaseV #AI Conductor

New PhaseV Survey Uncovers Critical Delays in Clinical Trials

A recent independent survey by PhaseV has shed light on the persistent challenges faced by sponsors in clinical trial reporting and data workflows. The findings are particularly striking, showing that a staggering 88% of sponsors are experiencing delays of five weeks or more. This prevalent issue is largely attributed to vendor fragmentation and repeated protocol amendments that are common in today's biopharmaceutical landscape.

The Root of the Problem

Conducted with over 50 senior executives from leading pharmaceutical and biotechnology companies, the survey titled The State of Clinical Trial Data Handoffs, Spend, Timelines, and Vendor Dynamics reveals that operational bottlenecks are creating significant financial burdens for sponsors. In fact, the accumulated costs for external workflows can exceed $3 million over the lifecycle of a program, which is alarming as these figures highlight an urgent need for operational improvements.

The data shows that while managing critical-path statistical programming and reporting, the average timeline extends well over five weeks. This delay not only hampers efficiency but also threatens to derail timelines crucial for getting new therapies to patients.

Key Findings

Among the pivotal revelations from the survey, we see:

• - Pre-Trial Delays: More than half of the respondents indicated that preliminary activities such as developing study synopses and protocols generally take between five to eight weeks, adding time-consuming barriers before trials even commence.
• - Reporting Bottlenecks: Operational challenges are not limited to pre-trial activities. Nearly three-quarters of respondents reported that late-stage documentation poses continued issues. For instance, one-third stated that creating statistical analysis plans (SAPs) and clinical study reports (CSRs) can take up to twelve weeks, while an additional 43% said these tasks generally require five to eight weeks.
• - Complexity and Costs: The complexity of managing multiple protocol amendments during Phase II and Phase III trials is staggeringly high, often leading to increased costs and significant delays. On average, sponsors noted that vendor costs escalate dramatically from $250,000 in Phase I to about $900,000 by Phase III.
• - Vendor Fragmentation: A worrying statistic from the report indicates that 76% of sponsors are using up to three vendors per trial, with 12% managing four to five different vendors. This fragmentation translates into multiplied manual handovers, which stagnates progress and contributes to inefficiencies.

The Need for Automation

With the increasing pressure to streamline research and development efficiency while slashing costs, the statistics paint a concerning picture of the current state of clinical trials. The costs linked with trial delays can range from $600,000 to as high as $8 million per day in opportunity losses. As such, the issue of prolonged reporting timelines signals a significant economic vulnerability in the industry.

Dr. Raviv Pryluk, CEO and Co-founder of PhaseV, aptly noted the urgency of addressing these inefficiencies. “When late-stage reporting can stretch to three months and teams are stuck juggling multiple vendors just to cross the finish line, the clinical development model is clearly broken.” To combat this issue, PhaseV has introduced its AI-driven platform, AI Conductor, designed to unify workflows and facilitate smoother transitions across various phases of clinical trials.

AI Conductor: A Solution

AI Conductor utilizes proprietary causal AI and machine learning technologies to automate essential trial documentation and statistical programming, covering everything from protocol drafting to regulatory submissions. This innovative platform is a game-changer as it replaces outdated, manual, and fragmented systems with an integrated approach, turning multi-week bottlenecks into processes that are completed in mere hours.

The platform stands out by dynamically generating all necessary documentation, including protocols, SAPs, ADaM datasets, and submission-ready assets, while ensuring strict compliance and readiness for audits. By streamlining the clinical trial lifecycle, AI Conductor aims to enhance efficiency and data quality while expediting the delivery of new therapies to patients.

For more detailed insights, you can download the full report from PhaseV. To see how AI Conductor can transform your clinical workflows, visit PhaseV AI Conductor for a demo or additional information.

About PhaseV

PhaseV, based in Boston, is at the forefront of advancing clinical development by leveraging Causal AI technology for decision-support. With successful backing for over 80 clinical trials and partnerships with major pharmaceutical companies, PhaseV is committed to driving efficiency across the industry. Learn more at PhaseVTrials.com and follow us on LinkedIn.